Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. - Barron's
1. Novo reports Q1 results as it seeks market share from Eli Lilly. 2. Wegovy sales projections for Q1 expected at 18.6 billion DKK. 3. Novo partners with telehealth firms for direct sales to consumers. 4. Novo's CVS deal may enhance Wegovy's accessibility at lower prices. 5. Eli Lilly gains leadership in incretin prescriptions, impacting Novo's market.